Recent studies demonstrate the growing role of artificial intelligence in biotech innovation. AI identified Bufalin as a novel estrogen receptor degrader, presenting potential new hormone receptor-targeted cancer therapies. Additionally, advanced AI/ML models are optimizing genome editing and RNA vaccine delivery, fostering faster therapeutic development. Notable collaborations include Natera’s AI foundational model for therapeutic discovery and Monash University’s targeted mRNA-LNP delivery platform advancing gene editing and immunotherapy.